Gilead, Merck agreement to develop HIV treatments lenacapavir and islatravir

The two pharma firms seek to transform HIV care with focus on long-acting therapies as the field of HIV treatment evolves to provide additional options for HIV sufferers and their physicians. Credit: National Cancer Institute/Unsplash.